Check for updates

OPEN ACCESS

EDITED BY Georgia Trakada, National and Kapodistrian University of Athens, Greece

REVIEWED BY

Mangala Hegde, Indian Institute of Technology Guwahati, India Jing Hong, Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, China

*CORRESPONDENCE Shan Wang wsaquarius@sina.com Jun Tai trenttj@163.com

[†]These authors have contributed equally to this work

RECEIVED 10 July 2023 ACCEPTED 09 July 2024 PUBLISHED 26 July 2024

CITATION

Yan W, Zhou J, Jiang M, Kong Y, Qin H, Qi Y, Wang S and Tai J (2024) Obstructive sleep apnea and 19 gastrointestinal diseases: a Mendelian randomization study. *Front. Psychiatry* 15:1256116. doi: 10.3389/fpsyt.2024.1256116

COPYRIGHT

© 2024 Yan, Zhou, Jiang, Kong, Qin, Qi, Wang and Tai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Obstructive sleep apnea and 19 gastrointestinal diseases: a Mendelian randomization study

Weiheng Yan^{1†}, Jiayi Zhou^{1†}, Miaomiao Jiang², Yaru Kong¹, Han Qin³, Yuwei Qi⁴, Shan Wang^{5*} and Jun Tai^{1*}

¹Department of Otolaryngology, Head and Neck Surgery, Children's Hospital Capital Institute of Pediatrics, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China, ³Children's Hospital Capital Institute of Pediatrics, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Otolaryngology, Head and Neck Surgery, Children's Hospital Capital Institute of Pediatrics, Beijing, China, ⁵Beijing Municipal Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Beijing, China

Background: Alterations gastrointestinal diseases (GDs) were reported in individuals with obstructive sleep apnea (OSA), however, the genetic background between OSA and GDs is still unclear.

Methods: This investigation employed Mendelian randomization (MR) analyses to evaluate the causal effect between OSA and 19 types of GDs (gastroesophageal reflux disease (GERD), ulcerative colitis, celiac disease, Crohn's disease, chronic gastritis, irritable bowel syndrome, primary biliary cholangitis, diverticular disease, gastroduodenal ulcer, acute pancreatitis, non-alcoholic fatty liver disease, primary sclerosing cholangitis, cirrhosis, calculus of bile duct, calculus of gallbladder, pancreatic cancer, gastric cancer, colorectal cancer, and esophageal cancer). The inverse-variance weighted (IVW) method was used to evaluate the main effects model of causality.

Results: This MR study suggests that OSA may play a causal role inflammation-related GDs (GERD, $P_{IVW}=5.94\times10^{-9}$; gastroduodenal ulcer, $P_{IVW}=1\times10^{-4}$; chronic gastritis, $P_{IVW}=0.0214$; ulcerative colitis, $P_{IVW}=0.0296$), and gallstones (calculi of the gallbladder, $P_{IVW}=0.0429$; calculi of the bile duct, $P_{IVW}=0.0068$). After accounting for obesity, type 2 diabetes, smoking, and alcohol consumption, the multivariate MR (MVMR) analysis identified that OSA is an independent risk factor for GERD, gastroduodenal ulcer, and calculus of the bile duct. The reverse MVMR analysis showed a causal effect of GERD on OSA. Besides, we did not find that the predisposition to OSA was associated with 4 cancers.

Conclusion: This MR analysis provides compelling evidence of an independent causal relationship between genetically predicted OSA and an elevated risk of inflammation-related GDs. Besides, no causal association was observed between OSA and cancers. Further studies should be carried out to verify our findings.

KEYWORDS

obstructive sleep apnea, gastrointestinal disease, Mendelian randomization, gastroesophageal reflux, causal relationship

01

1 Introduction

Obstructive sleep apnea (OSA) is the most prevalent form of sleep-disordered breathing with a global prevalence rate of 9–38% (1, 2). OSA can lead to intermittent hypoxemia, sleep fragmentation, sympathetic hyperactivity, variations in intrathoracic pressure, and disturbances in physiological balance (3). These symptoms greatly decrease one's quality of life and increase morbidity of other diseases (4, 5).

The quality of sleep and sleep-related breathing disorders constitute significant factors contributing to the development of Gastrointestinal diseases (GDs) (6). Observational cohort studies have consistently indicated a higher prevalence of GDs among individuals with OSA compared to those without, encompassing conditions such as gallstones (7), non-alcoholic fatty liver disease (NAFLD) (8), inflammatory bowel disease (IBD) (9) and gastroesophageal reflux disease (GERD) (10-12). A retrospective study involving 586,377 adults in the USA revealed an independent association between OSA and GERD, accounting for multiple potential confounding variables (13). Continuous positive airway pressure (CPAP) therapy has demonstrated efficacy in alleviating gastroesophageal reflux symptoms and stabilizing NAFLD progression in patients with OSA (14, 15). However, these findings have encountered scrutiny in recent research (16-18). At present, there is limited evidence of associations between OSA and other common gastrointestinal disorders. In summary, the causal link between OSA and GDs remains contentious, with debates centering on potential confounders and reverse causation biases. A comprehensive evaluation of this causal relationship is crucial to unraveling the mechanisms underlying disease co-occurrence and identifying therapeutic strategies that benefit both conditions.

Mendelian randomization (MR) provides a more precise evaluation of causality for exposure–outcome associations by leveraging genetic variations as instrumental variables (IVs) (19– 21). By generating genotypes through randomly assigning parental alleles during conception, MR minimizes the possibility of potential residual confounders and reverse causalities that could be influenced by environmental and self-imposed factors (22). MR has been widely used to predict causal pathways in studies examining the effects of OSA on atrial fibrillation (23), interleukin levels (24), and neurodegenerative disease (25). However, the effects of OSA on a broad range of gastrointestinal outcomes have not been investigated.

We performed a two-sample MR analysis and multivariate Mendelian randomization (MVMR) to evaluate whether OSA and common GDs are causally related. In addition, we used the same MR analysis methods in the reverse direction to determine whether GDs increased susceptibility to OSA.

2 Methods

2.1 Study design and genetic variants

We performed a bidirectional two-sample MR analysis to explore the causal relationships between OSA and the risk of developing one of 19 GDs. A flowchart of the study design is presented in Figure 1. The validity of genetic instruments is based on three critical principles. First, genetic variants employed as IVs should exhibit high confidence in their association with risk factors. Second, the chosen IVs should be independent of confounders that can influence the outcome. Third, IVs should not affect the outcome directly but only through their respective exposure traits (26, 27).

2.2 Data sources and IV selection

The analysis used summary-level data from publicly available GWAS projects and consortia to investigate the potential correlation between OSA and 19 GDs. No overlapping data on exposures and outcomes were permitted, minimizing the likelihood of statistical bias. Each GWAS used in the study obtained approval from the relevant ethics committees. Table 1 provides an overview of the source information for the GWAS data incorporated in this study.

2.2.1 Data sources of OSA

The statistical GWAS data for OSA were obtained from the FinnGen project (DATA FREEZE 8, https://www.finngen.fi/en), the largest independent GWAS project. The FinnGen data was preferred because it minimized the confounding bias caused by overlapping populations. Therefore, GWAS summary statistics obtained from 33,423 patients with OSA and 307,648 controls were included in this FinnGen study. The criteria for the diagnosis of OSA were an apnea-hypopnea index \geq 5/h or respiratory event index \geq 5/h (28).

2.2.2 Data sources of GDs

A total of 19 common gastrointestinal diseases were included in this study. The GWAS summary-level data for the relationships between genetic variants and 18 types of GDs were obtained from the Integrative Epidemiology Unit (IEU) open GWAS project (https://gwas.mrcieu.ac.uk/). The GDs included GERD, gastroduodenal ulcer, gastric cancer, Crohn's disease, ulcerative colitis, colorectal cancer, cirrhosis, primary sclerosing cholangitis, primary biliary cholangitis, chronic gastritis, esophageal cancer, calculus of the gallbladder, calculus of the bile duct, irritable bowel syndrome, celiac disease, diverticular disease, and acute pancreatitis. The summary-level data from the GWAS on NAFLD were obtained from the study by Anstee et al. (29).

2.2.3 Sample overlap between exposure and outcome GWAS summary statistics

The GWAS summary data for OSA utilized in this research was derived from the Finngen Project, an independent GWAS endeavor (28). This guarantees no sample overlap between the OSA GWAS summary statistics and the GDs-related GWAS statistics, thus ensuring the strength of the MR results.

2.2.4 Selection of genetic IVs

For global screening of IVs, genome-wide significance level ($p < 1 \times 10^{-05}$) was used as a threshold for screening IVs significantly



FIGURE 1

Study flow diagram. (A) The flow of Two-Sample MR analysis. (B) The flow of MVMR analysis. The dashed lines represent possible pleiotropic or direct causal effects between variables that may violate the MR assumptions. IVW, inverse-variance weighted; WM, weighted median; MR, Mendelian randomization; MR-PRESSO, MR pleiotropy residual sum and outlier; OSA, Obstructive sleep apnea; GDs, gastrointestinal diseases; IVs, instrumental variables; MVMR, Multivariate Mendelian randomization; LASSO, least absolute shrinkage and selection operator

associated with exposure factors. This threshold ensures a significant association between IVs and exposure factors while ensuring that as many IVs as possible are obtained for subsequent analysis (30). A minor allele frequency threshold of 0.3 was permitted for palindromic single nucleotide polymorphisms (SNPs). SNPs with low linkage disequilibrium were excluded with a strict r² cutoff of 0.001 and a clumping window greater than 10,000 kb. Detailed information on the SNPs employed as IVs is provided in Supplementary Table S1. As shown in Supplementary Table S1, the genome-wide significance p value between all IVs included in the analysis and the outcome phenotype was greater than 1×10^{-05} . This ensured that there was no direct correlation between IVs and outcome phenotypes. To prevent weak instrument bias, the statistical strength of IVs was evaluated by calculating the F-statistic. When the F-statistic is greater than 10, IV is considered to have good statistical performance (31, 32):

$$\mathbf{F} = \left(\frac{\mathbf{R}^2}{1 - \mathbf{R}^2}\right) \left(\frac{\mathbf{n} - \mathbf{k} - 1}{\mathbf{k}}\right)$$

In this context, R² denotes the fraction of variability in exposure that can be ascribed to genetic variants. The variable n denotes the sample size of the exposed phenotype, and k represents the total number of IVs included in each MR analysis.

2.3 Statistical analyses

All statistical analyses were performed using R version 4.1.1 (R Foundation for Statistical Computing; Vienna, Austria). The twosample MR analysis was performed utilizing the TwoSampleMR package (version 0.5.6); the MVMR analysis was performed using the MVMR package (version 0.3).

Disease	Source	PMID	Population	Ncase	Ncontrol
Gastroesophageal reflux disease	https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90000514/	34187846	European	129080	473524
Celiac disease	https://gwas.mrcieu.ac.uk/datasets/ieu-a-276/	20190752	European	4533	10750
Crohn's disease	https://gwas.mrcieu.ac.uk/datasets/ukb-a-552/	NA	European	732	336467
Colorectal cancer	https://gwas.mrcieu.ac.uk/datasets/ieu-b-4965/	NA	European	5657	372016
Chronic gastritis	https://gwas.mrcieu.ac.uk/datasets/ukb-d-K11_CHRONGASTR/	NA	European	1790	359404
Irritable bowel syndrome	https://gwas.mrcieu.ac.uk/datasets/ukb-b-17961/	NA	European	1047	461963
Oesophageal cancer	https://gwas.mrcieu.ac.uk/datasets/ieu-b-4960/	NA	European	740	372016
Primary biliary cholangitis	https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST003129/	26394269	European	2764	10475
Diverticular disease	https://gwas.mrcieu.ac.uk/datasets/ukb-b-10859/	NA	European	8429	454581
Gastroduodenal ulcer	https://gwas.mrcieu.ac.uk/datasets/ukb- d-K11_GASTRODUOULC/	NA	European	3467	357727
Calculus of bile duct	https://gwas.mrcieu.ac.uk/datasets/ukb-b-8268/	NA	European	1706	461304
Ulcerative colitis	https://gwas.mrcieu.ac.uk/datasets/ukb-b-7584/	NA	European	2439	460494
Calculus of gallbladder	https://gwas.mrcieu.ac.uk/datasets/ukb-b-8988/	NA	European	3932	459078
Acute pancreatitis	https://gwas.mrcieu.ac.uk/datasets/ukb-b-19388/	NA	European	1215	461795
Non-alcoholic fatty liver disease	https://www.ebi.ac.uk/gwas/studies/GCST90011885	32298765	European	1483	17781
Primary sclerosing cholangitis	https://gwas.mrcieu.ac.uk/datasets/ieu-a-1112/	27992413	Mixed	2871	12019
Cirrhosis	https://gwas.mrcieu.ac.uk/datasets/bbj-a-105/	NA	East Asian	2184	210269
Pancreatic cancer	https://gwas.mrcieu.ac.uk/datasets/bbj-a-140/	NA	East Asian	442	195745
Gastric cancer	https://gwas.mrcieu.ac.uk/datasets/bbj-a-119/	NA	East Asian	6563	195745
OSA	https://www.finngen.fi/en	NA	European	33423	307648
Obesity	https://www.finngen.fi/en	NA	European	18330	324070
Smoking	https://www.finngen.fi/en	NA	European	2922	133128
Type 2 diabetes	https://www.finngen.fi/en	NA	European	49114	283207
Alcohol abuse	https://www.finngen.fi/en	NA	European	4334	254976

TABLE 1 GWAS summary data sources used in Two-Sample MR analysis and MVMR analysis.

GWAS, Genome Wide Association Study; MR, Mendelian randomization; MVMR, multivariate Mendelian randomization; OSA, Obstructive sleep apnea; GDs, gastrointestinal diseases; Ncase, Number of cases; Ncontrol, Number of control samples.

2.3.1 Two-sample MR analysis

The principal method adopted in this research for determining the causal association between OSA and GDs was the IVW approach using a random-effects model. To ensure the reliability of the results and identify potential horizontal pleiotropy, multiple sensitivity analyses were carried out, inclusive of the weighted median, MR-Egger, weighted mode, and simple mode methods. Each of these analyses relies on distinct assumptions necessary for making valid inferences. The IVW method computes the effect as the IVW average of the ratio estimates of SNPs, with first-order weights based on each SNP serving as a valid IV (26, 33). The weighted-median method requires >50% of the chosen genetic instruments to be valid; the weighted mode produces reliable outcomes when the percentage of invalid instruments exceeds 50% (34). The MR-Egger method can yield a valid estimate of causal effects even if all SNPs are invalid instruments because it employs weighted regression without a restricted intercept (35). The weighted mode method is also resilient against invalid or pleiotropic SNPs, taking the IVW empirical density function mode as an effect estimate (36). The reliability of the causal inference conclusions is enhanced when the findings of all the methods are broadly consistent. However, causality inferred from other methods may have greater confidence intervals and standard errors than those derived from IVW (32, 37).

This study's causal effect estimates of genetically predicted OSA on GDs are expressed as ORs with corresponding 95% CIs. The Bonferroni correction for multiple testing was conducted to correct P values. A P value less than 1.32×10^{-03} (0.05/19/2; 2 denotes both forward and reverse MR tests) was considered as strong evidence of a causal association. A value of p<0.05 was considered suggestive of a correlation.

2.3.2 MVMR analysis

Because obesity, T2D, smoking, and alcohol consumption are common risk factors for most GDs and OSA, MVMR analysis was used to estimate the risk effect of OSA on GDs after adjusting for these risk factors (38, 39). By integrating several risk exposures into the MR Analysis concurrently, MVMR elucidates whether each discrete risk exposure has an independent causal effect on the outcome when multiple risk exposures co-exist (40). In this research, OSA was amalgamated with the aforementioned four common risk factors as an exposure variable, and an MVMR model was assembled to assess whether OSA exposure had a direct association with GDs outcomes. Given that collinearity bias may be introduced if excessive exposure variables are incorporated in the MVMR model simultaneously, this study used each common risk factor individually with OSA exposure to construct an MVMR model. MVMR-Robust, MVMR-IVW, and the least absolute shrinkage and selection operator (LASSO) were used to determine the independent effects of OSA on GDs (41). Table 1 provides an overview of the source information for the risk-factors-related GWAS data used in MVMR analysis incorporated in this study. Reverse MVMR analysis using the same strategy determined the independent effect of GDs exposure on the risk of OSA outcomes.

2.4 Pleiotropy and sensitivity analysis

Cochran's Q-test of the IVW and MR-Egger methods was used to assess heterogeneity. Pleiotropy was evaluated using the intercept of the MR-Egger analysis. The Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) approach was used to identify potential outlier SNPs through a global test, repeating the analysis after eliminating the outlying SNPs. This method provides a distortion test that can compare differences before and after removing outliers (37). Funnel plots were used to show the discrete relationships between SNPs and as a complementary basis for removing potential outliers. The Steiger directionality test was utilized to ascertain the causal direction between the assumed exposure and potential outcomes. This test can determine whether the genetic variant used as an IV for the exposure trait is also causally related to the outcome or whether it influences the outcome through the exposure trait (42). Leave-one-out analysis was performed by omitting each SNP to evaluate whether a single SNP influenced or resulted in remarkable MR results (43).

3 Results

For this investigation, the globally significant threshold for IVs screening was set at $p<1\times10^{-5}$, $r^2 = 0.001$, and a clumping window >10,000 kb. Based on these criteria, 747 SNPs were selected as IVs to evaluate causal relationships linking OSA to all 19 GDs, using OSA as the exposure factor. Unfortunately, when GDs were utilized as exposure factors during reverse MR analysis, the IVs that could be extracted from the genome-wide association study (GWAS) summary data on calculus of the bile duct and acute pancreatitis were insufficient. Consequently, no causal association between these

two conditions and OSA was identified. The included IVs are detailed in Supplementary Table S1. Supplementary Table S2 presents the IVs featured in the MR analysis that identified a potential causal link between OSA and GDs.

3.1 Causal effect of genetically predicted OSA on GDs

Utilizing the two-sample MR method, with liability to OSA as the exposure and the risk of 19 GDs as outcomes, our analysis found that a genetic inclination towards OSA exhibited an association with 6 types of GDs risk (p < 0.05). According to IVW method, OSA exposure was significantly associated with an increased risk of GERD and gastroduodenal ulcer ($p < 1.32 \times 10^{-03}$). Genetically predicted OSA was significantly associated with a 1.1669 greater odds of GERD (95% confidence interval [CI]: 1.1078–1.2292, $p=5.94\times10^{-9}$; Figure 2A), 1.0019 greater odds of gastroduodenal ulcer (95% CI: 1.0010–1.0029; $p=1\times10^{-4}$). And OSA shows a suggestive correlation with 1.0008 greater odds of chronic gastritis (95% CI: 1.0001–1.0015; p=0.0214). The effect estimates from the sensitivity analysis methods (weighted median, MR-Egger, weighted mode, and simple mode methods) were consistent with IVW method.

We also observed suggestive causal associations between genetically predicted OSA with ulcerative colitis (Odds ratio [OR] $_{\rm IVW}$ =1.0010, 95% CI: 1.0001–1.0019, p=0.0296) and gallstones, including calculi of the gallbladder (OR_{IVW} =1.0011, 95% CI: 1.0000–1.0021, p=0.0429) and calculi of the bile duct (OR_{IVW} =1.0013, 95% CI: 1.0004–1.0023, p=0.0068). However, these causal associations were weakened in MR-Egger method, but effect estimates from other sensitivity analysis methods (weighted median, weighted mode, and simple mode methods) were still consistent with IVW method. (Figure 2B). The risk of the other 13 types of GDs was not significantly associated with genetically predicted OSA according to the MR analysis.

MVMR analysis indicated that OSA was an independent risk factor for GERD, gastroduodenal ulcer, and calculus of bile duct (Figures 3, 4). However, the effects of OSA on chronic gastritis (adjusted $OR_{IVW} = 1.0007$, p=0.0970), ulcerative colitis (adjusted $OR_{IVW} = 1.0007$, p=0.0970), and gallbladder calculus (adjusted $OR_{IVW} = 1.0019$, p=0.3621) were no longer significant in MVMR analysis after considering obesity (Figure 4).

3.2 Causal effect of genetically predicted GDs on OSA

In the reversed-direction MR study, the potential causal effects of genetically predicted liability for each GD's exposure on OSA were estimated using the factors found to be statistically significant (p<0.05). Acute pancreatitis and calculus of the bile duct were excluded from the MR analysis because of insufficient IVs (IVs < 3).

The reverse MR analysis showed that GERD had a remarkable causal effect on OSA, demonstrated by an effect estimate of 1.3907 (95% CI: 1.3154-1.4705, p= 4.17×10^{-31}) for GERD using the IVW

Α

D

Exposure: Outcome	No. of SNPs	Pvalue	Beta	SE		OR (95% CI)
OSA: Gastroesophageal reflux dise	ease					
MR Egger	31	0.6168	0.0697	0.1378	•	1.0722 (0.8185 to 1.4045)
Weighted median	31	6.06e-06	0.1544	0.0341		1.1669 (1.0914 to 1.2476)
Inverse variance weighted	31	5.94e-09	0.1544	0.0265	-	1.1669 (1.1078 to 1.2292)
Simple mode	31	0.0542	0.1697	0.0847		1.1849 (1.0037 to 1.3989)
Weighted mode	31	0.0592	0.1628	0.083	_ 	1.1768 (1.0001 to 1.3848)
Gastroesophageal reflux disease:	OSA					
MR Egger	195	0.003	0.4275	0.1421	.	1.5335 (1.1608 to 2.0259)
Weighted median	195	6.34e-22	0.3422	0.0356		1.4081 (1.3133 to 1.5097)
Inverse variance weighted	195	4.17e-31	0.3298	0.0284	-	1.3907 (1.3154 to 1.4705)
Simple mode	195	0.0015	0.3798	0.1178	_	1.4619 (1.1606 to 1.8416)
Weighted mode	195	0.0012	0.3798	0.1158	-	1.4619 (1.1652 to 1.8343)
# Multiplicative Random Effects was used for IVW				0.5	1 1.5 2	2.5

Decreased Risk Increased Risk

DSA: Gastroduodenal ulcer MR Egger Weighted median Inverse variance weighted	116					
MR Egger Weighted median Inverse variance weighted	116					
Weighted median Inverse variance weighted	440	0.4048	9e-04	0.0011		1.0009 (0.9988 to 1.0030)
Inverse variance weighted	116	0.0038	0.0022	8e-04		1.0022 (1.0007 to 1.0037
0	116	1e-04	0.0019	5e-04		1.0019 (1.0010 to 1.0029
Simple mode	116	0.1287	0.0028	0.0018		1.0028 (0.9992 to 1.0064
Weighted mode	116	0.0323	0.0027	0.0012	_	1.0027 (1.0003 to 1.0052
OSA: Chronic gastritis						
MR Egger	113	0.393	7e-04	8e-04		1.0007 (0.9991 to 1.0022)
Weighted median	113	0.2987	6e-04	6e-04		1.0006 (0.9995 to 1.0017
Inverse variance weighted	113	0.0214	8e-04	4e-04		1.0008 (1.0001 to 1.0015
Simple mode	113	0.17	0.002	0.0015		1.0020 (0.9991 to 1.0049)
Weighted mode	113	0.8747	1e-04	9e-04		1.0001 (0.9983 to 1.0020)
OSA: Ulcerative colitis						
MR Egger	64	0.5151	-0.0015	0.0022 —		0.9985 (0.9941 to 1.0029)
Weighted median	64	0.48	5e-04	7e-04		1.0005 (0.9992 to 1.0017
Inverse variance weighted	64	0.0296	0.001	5e-04		1.0010 (1.0001 to 1.0019
Simple mode	64	0.9239	1e-04	0.0015		1.0001 (0.9973 to 1.0030)
Weighted mode	64	0.9932	0	0.0012	_	1.0000 (0.9977 to 1.0023)
SA: Calculus of gallbladder	r					
MR Egger	77	0.9202	-2e-04	0.0022 —		0.9998 (0.9954 to 1.0042)
Weighted median	77	0.2287	9e-04	8e-04		1.0009 (0.9994 to 1.0024
Inverse variance weighted	77	0.0429	0.0011	5e-04		1.0011 (1.0000 to 1.0021
Simple mode	77	0.5173	0.0011	0.0017		1.0011 (0.9977 to 1.0045
Weighted mode	77	0.5313	9e-04	0.0015		1.0009 (0.9980 to 1.0039)
OSA: Calculus of bile duct						
MR Egger	47	0.3073	-0.0028	0.0027 ———		0.9973 (0.9921 to 1.0025
Weighted median	47	0.2298	8e-04	6e-04		1.0008 (0.9995 to 1.0020)
Inverse variance weighted	47	0.0068	0.0013	5e-04		1.0013 (1.0004 to 1.0023
Simple mode	47	0.7224	6e-04	0.0016		1.0006 (0.9974 to 1.0038)
Weighted mode	47	0.9736	0	0.0015		1.0000 (0.9972 to 1.0029)
Multiplicative Random Effec	ts was used f	or IVW		0.99	1 1	01

FIGURE 2

A forest plot of the potential causal relationship between OSA and GDs. (A) The forest plot of the potential causal relationship between OSA and GERD; (B) The forest plot of the potential causal relationship between OSA and other GDs. OSA, Obstructive sleep apnea; GERD, gastroesophageal reflux disease; GDs, gastrointestinal diseases; SNP, single nucleotide polymorphism; OR, odds ratio; SE, standard error; CI, confidence interval; IVW, inverse-variance weighted.

method (Figure 2A). This result is in line with the outcomes from other methods, including MR-Egger (OR=1.5335, 95% CI: 1.1608–2.0259, p=0.0029) and the weighted-median method (OR=1.4081, 95% CI: 1.3033–1.5097, p= 6.34×10^{-22}), which showed significant associations with greater confidence intervals. Genetically predicted GERD remained associated with OSA after accounting for obesity, type 2 diabetes (T2D), smoking, and alcohol consumption in the MVMR analysis (Figure 3). Other genetically determined GDs were not observed to be significantly associated with OSA risk. The detailed reverse MR results are presented in Supplementary Table S3.

3.3 Sensitivity analysis

A total of six types of GDs were found to be causally correlated with OSA by Two-sample MR analysis. A total of 331 IVs were used in those MR analysis, corresponding to F- statistic ranging from 137.26 to 1228.67 (F-statistic > 10), which ensured that there was no weak instrument bias in the included IVs (Supplementary Table S2). A variety of methods were used to evaluate the dispersion and heterogeneity among IVs. The scatter plots (Supplementary Figure S1) and funnel plot (Supplementary Figure S2) shows the distribution of IVs in the potential causal relationship between

Confounding bias	Method	Pvalue		OR (95% CI)
(Exposure to Outcomes) Gas	stroesophageal reflux dis	ease: OSA	1	
alcohol	mvmr_ivw	3.84e-22		1.4325 (1.3319 to 1.540)
alcohol	mvmr_robust	2.02e-23		1.4101 (1.3180 to 1.508
alcohol	mvmr_lasso	2.72e-35		1.4209 (1.3441 to 1.502)
(Exposure to Outcomes) Gas	stroesophageal reflux dis	ease: OSA		
obesity	mvmr_ivw	1.06e-06		1.2402 (1.1375 to 1.352
obesity	mvmr_robust	9.35e-13		1.3299 (1.2298 to 1.438
obesity	mvmr_lasso	2.13e-16		1.3439 (1.2524 to 1.442
(Exposure to Outcomes) Gas	stroesophageal reflux dis	ease: OSA		
smoke	mvmr_ivw	3.69e-23		1.4711 (1.3630 to 1.587)
smoke	mvmr_robust	7.1e-24	-•-	1.4499 (1.3488 to 1.558
smoke	mvmr_lasso	2.99e-37		1.4792 (1.3928 to 1.5710
(Exposure to Outcomes) Gas	stroesophageal reflux dis	ease: OSA		
T2D	mvmr_ivw	3e-17		1.4285 (1.3150 to 1.551)
T2D	mvmr_robust	1.16e-17		1.4125 (1.3051 to 1.5288
T2D	mvmr_lasso	2.51e-30		1.4372 (1.3506 to 1.5293
(Exposure to Outcomes) OS	A: Gastroesophageal refl	ux disease		
alcohol	mvmr_ivw	2.12e-08	-	1.2045 (1.1286 to 1.285
alcohol	mvmr_robust	0.0002		1.1962 (1.0871 to 1.316)
alcohol	mvmr_lasso	6.77e-10	-	1.1898 (1.1259 to 1.257
(Exposure to Outcomes) OS	A: Gastroesophageal refl	ux disease		
obesity	mvmr_ivw	0.0141		1.0952 (1.0185 to 1.177
obesity	mvmr_robust	0.0340		1.0939 (1.0068 to 1.188
obesity	mvmr_lasso	0.056222501	a -	1.0577 (0.9985 to 1.1203
(Exposure to Outcomes) OS	A: Gastroesophageal refl	ux disease		
smoke	mvmr_ivw	6.58e-08		1.1967 (1.1212 to 1.277)
smoke	mvmr_robust	0.0002		1.1919 (1.0882 to 1.305)
smoke	mvmr_lasso	2.4e-08	-	1.1531 (1.0969 to 1.212
(Exposure to Outcomes) OS	A: Gastroesophageal refl	ux disease		
T2D	mvmr_ivw	7.35e-11	-	1.2142 (1.1453 to 1.287)
T2D	mvmr_robust	7.75e-08		1.2175 (1.1332 to 1.308)
T2D	mvmr_lasso	2.69e-16	-	1.2007 (1.1492 to 1.254
# Multiplicative Random Effect	s was used for IVW	0.5	1 1.5 2	2.5
		Decreased I	Risk Increased Risk	

A forest plot of the MVMR results between OSA and GERD. OSA, Obstructive sleep apnea; GERD, gastroesophageal reflux disease; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted; LASSO, least absolute shrinkage and selection operator; MVMR, multivariate Mendelian randomization.

OSA and 6 types of GDs. The leave-one-out analysis showed that single IVs had little effect on the causal association between OSA and GDs (Supplementary Figures S3-S9).

The Cochran's Q test was used to identify potential heterogeneity. Supplementary Table S4 shows Cochran's Q test results. In the significant causal association between OSA exposure and GDs outcomes, no heterogeneity was found between IVs ($P_{Cochran's Q} > 0.05$). When GERD is an exposure factor, the potential causal association with OSA outcome may be influenced by heterogeneity ($P_{Cochran's Q} < 0.05$). Therefore, the random-effects IVW method was used in this study to eliminate the bias caused by possible heterogeneity.

The MR-Egger intercept analysis was used for the potential horizontal pleiotropy of MR Analysis between OSA and GDs. On the whole, horizontal pleiotropy was not discovered by MR-Egger intercept analysis. (P > 0.05, Supplementary Table S5). MR-PRESSO was used to identify potential outlier IVs and to supplement the evaluation of level pleiotropy. Four potential outliers were detected in the MR-PRESSO analysis of the effect of OSA on GERD. After those IVs removal, horizontal pleiotropy was eliminated. However, in the reverse-MR analysis, possible underlying heterogeneity for the effect

of GERD on OSA persisted after eliminating the two SNP outliers (MR-PRESSO Globle Test Pvalue < 0.05, Supplementary Table S6). The MR Steiger's test did not find a potential reverse causal association affecting the robustness of the results (Table 2).

4 Discussion

This MR analysis is the first to systematically evaluate the causeand-effect relationship between OSA and digestive disorders. Twosample MR analysis found a strong correlation between OSA and the incidence of gastroduodenal ulcer and GERD. A nominal causal association was found between OSA and increased risk of calculus of bile duct, calculus of gallbladder, chronic gastritis, and ulcerative colitis. The MVMR analysis found a reciprocal causal link between OSA and GERD. After adjusting for four risk factors (obesity, T2D, smoking, and alcohol consumption) in MVMR analysis, OSA increases the risk of gastroduodenal ulcer and calculus of the bile duct independently.

Numerous epidemiological studies have provided compelling evidence linking several gastrointestinal disorders to sleep disorders such as OSA (6, 10, 44). OSA can induce intermittent hypoxemia,

ontounding bias	Method	٢			UH (95% CI)
Exposure to Outcomes) OSA:	Calculus of bil	e duct			
aicohol	mvmr_ivw	0.0049	-		1.0014 (1.0004 to 1.0024)
alcohol	mvmr_robust	0.0153			1.0014 (1.0003 to 1.0025)
alcohol	mvmr_lasso	3e-04			1.0017 (1.0008 to 1.0027)
Exposure to Outcomes) OSA:	Calculus of bil	e duct			
obesity	mvmr_ivw	0.0422			1.0012 (1.0000 to 1.0023)
obesity	mvmr_robust	0.0278			1.0012 (1.0001 to 1.0022)
obesity	mvmr_lasso	0.038			1.0011 (1.0001 to 1.0021)
Exposure to Outcomes) OSA:	Calculus of bil	e duct			
smoke	mvmr_ivw	0.0018			1.0016 (1.0006 to 1.0026)
smoke	mvmr_robust	0.008			1.0016 (1.0004 to 1.0027)
smoke	mvmr_lasso	1e-04			1.0019 (1.0009 to 1.0028)
Exposure to Outcomes) OSA:	Calculus of bil	e duct			
T2D	mvmr_ivw	2e-04			1.0016 (1.0008 to 1.0025)
T2D	mvmr_robust	0.0017			1.0016 (1.0006 to 1.0026)
T2D	mymr lasso	3e-04			1.0015 (1.0007 to 1.0024)
Exposure to Outcomes) OSA:	Calculus of ga	libladder			,
alcohol	mymr ivov	0.0277	-		1.0011 (1.0001 to 1.0022)
alcohol	mymr_robust	0.0144			1.0012 (1.0002 to 1.0021)
alcohol	mumr loooo	0.000			1.0012 (1.0002 to 1.0021)
aconol	Coloulus of	U.UU9			1.0014 (1.0003 to 1.0024)
Exposure to Outcomes) OSA:	calculus of ga	IIDiadder			4 0000 (0 0007)
obesity	mvmr_ivw	0.3621 -	•		1.0006 (0.9993 to 1.0019)
obesity	mvmr_robust	0.2049 -			1.0008 (0.9996 to 1.0020)
obesity	mvmr_lasso	0.1397 -	•		1.0009 (0.9997 to 1.0021)
Exposure to Outcomes) OSA:	Calculus of ga	llbladder			
smoke	mvmr_ivw	0.0614			1.0010 (1.0000 to 1.0021)
smoke	mvmr_robust	0.0307			1.0011 (1.0001 to 1.0021)
smoke	mvmr_lasso	0.0577			1.0010 (1.0000 to 1.0021)
Exposure to Outcomes) OSA:	Calculus of ga	llbladder			
T2D	mymr ivw	0.0122			1.0013 (1.0003 to 1.0023)
T2D	mymr_robust	0.0061	-		1.0014 (1.0004 to 1.0024)
T2D	mymr locco	0.0064			1.0013 (1.0004 to 1.0024)
Exposure to Outcomes' OSA:	Chronic as -t-	0.0004	-		1.0013 (1.0004 to 1.0023)
Exposure to Outcomes) USA:	unronic gastri	0.0057	_		4 0000 /4 0001 - 1 001-
aicoñol	mvmr_ivw	0.0257	-		1.0008 (1.0001 to 1.0015)
aiconol	mvmr_robust	0.0259	-		1.0008 (1.0001 to 1.0015)
alcohol	mvmr_lasso	0.0125	-		1.0009 (1.0002 to 1.0016)
Exposure to Outcomes) OSA:	Chronic gastri	tis			
obesity	mvmr_ivw	0.097	-		1.0007 (0.9999 to 1.0015)
obesity	mvmr_robust	0.1364	-		1.0007 (0.9998 to 1.0015)
obesity	mvmr_lasso	0.8864			1.0003 (0.9961 to 1.0045)
Exposure to Outcomes) OSA:	Chronic gastri	tis			
smoke	mvmr_ivw	0.0371	-		1.0007 (1.0000 to 1.0014)
smoke	mymr robust	0.0293			1.0008 (1.0001 to 1.0015)
smoke	mymr laceo	0.0195	-8-		1.0008 (1.0001 to 1.0015)
Exposure to Outcomor) CCA:	Chronic cach	tie			
TOD	mane jaw	0.0050	-		1 0000 (1 0002 to 1 0010)
120	mvmr_i/w	0.0059	-		1.0009 (1.0003 to 1.0016)
120	mvmr_robust	0.0061	-		1.0010 (1.0003 to 1.0017)
120	mvmr_lasso	0.0027	•		1.0010 (1.0004 to 1.0017)
Exposure to Outcomes) OSA:	Gastroduoden	al ulcer			
alcohol	mvmr_ivw	1e-04			1.0019 (1.0009 to 1.0029)
alcohol	mvmr_robust	3e-04			1.0019 (1.0009 to 1.0029)
alcohol	mvmr_lasso	0.4346			1.0022 (0.9967 to 1.0077)
Exposure to Outcomes) OSA:	Gastroduoden	al ulcer			
obesity	mymr iyw	0.0013			1.0019 (1.0007 to 1.0030)
obesity	mymr rohuet	0.0032	_ _		1.0018 (1.0006 to 1.0030)
obesity	mumr laces	0.002			1.0018 (1.0006 to 1.0030)
Exposure to Outcomes) CO.4	Gaetroduod	alulcar			
emoke	Gasuoduoden	10.04			1 0010 (1 0000 1- 1 0000)
SITIUKE	mvmr_ivw	10-04			1.0019 (1.0009 to 1.0029)
smoke	mvmr_robust	10-04			1.0019 (1.0009 to 1.0029)
smoke	mvmr_lasso	7e-04			1.0017 (1.0007 to 1.0026)
Exposure to Outcomes) OSA:	Gastroduoden	al ulcer			
T2D	mvmr_ivw	7.35e-11			1.2142 (1.1453 to 1.2872)
T2D	mvmr_robust	7.75e-08		-	1.2175 (1.1332 to 1.3082)
T2D	mvmr_lasso	2.69e-16			1.2007 (1.1492 to 1.2544)
Exposure to Outcomes) OSA:	Ulcerative col	itis			
alcohol	mvmr_ivw	0.0257	-		1.0008 (1.0001 to 1.0015)
alcohol	mvmr_robust	0.0259			1.0008 (1.0001 to 1.0015)
alcohol	mymr laceo	0.0125	-		1,0009 (1,0002 to 1,0016)
Exposure to Outcomos) CCA	Illearative c=1	itie			
obesity	mumr. hav	0.097			1 0007 (0 0000 to 1 0015)
opeany	mvmr_ivw	0.037			1.0007 (0.9999 to 1.0015)
obesity	mvmr_robust	0.1364	-		1.0007 (0.9998 to 1.0015)
obesity	mvmr_lasso	0.8864	•		1.0003 (0.9961 to 1.0045)
Exposure to Outcomes) OSA:	Ulcerative col	ıtis			
smoke	mvmr_ivw	0.0371			1.0007 (1.0000 to 1.0014)
smoke	mvmr_robust	0.0293			1.0008 (1.0001 to 1.0015)
	mvmr_lasso	0.0195			1.0008 (1.0001 to 1.0015)
smoke		itie			
smoke Exposure to Outcomes) OSA:	Ulcerative coli	100			
smoke Exposure to Outcomes) OSA:	Ulcerative col	0.0059			1 0009 (1 0003 to 1 0016)
smoke Exposure to Outcomes) OSA: T2D	Ulcerative col mvmr_ivw	0.0059			1.0009 (1.0003 to 1.0016)
smoke Exposure to Outcomes) OSA: T2D T2D	Ulcerative col mvmr_ivw mvmr_robust	0.0059 0.0061			1.0009 (1.0003 to 1.0016) 1.0010 (1.0003 to 1.0017)

FIGURE 4

A forest plot of the MVMR results between OSA and other GDs. OSA, Obstructive sleep apnea; GDs, gastrointestinal diseases; OR, odds ratio; Cl, confidence interval; IVW, inverse-variance weighted; LASSO, least absolute shrinkage and selection operator; MVMR, multivariate Mendelian randomization.

sleep fragmentation, oxidative stress, systemic inflammatory response, and disrupt intestinal flora, potentially contributing to the onset of gastrointestinal diseases. Conversely, nocturnal awakenings, sleep deprivation and sleep fragmentation due to gastrointestinal diseases may reciprocally influence the occurrence of OSA. However, the causal relationship remains unclear due to limitations in temporal sequencing in existing observational studies. To address this gap, we conducted bidirectional MR and MVMR analyses to robustly evaluate the causal connections between OSA and common GDs, providing robust evidence of their causal associations. This findings underscores the importance of early screening for these disorders in OSA-diagnosed patients.

TABLE 2 Results of sensitivity analysis of MR Analysis.

Exposure	Outcome	Fstat	Cochrane Q_pvalue	Pleiotropy pvalue	MR- PRESSO pvalue	Stieger test
OSA	GERD	280.91	0.06	0.54	0.10	TRUE
OSA	Gastroduodenal ulcer	323.26	0.35	0.26	0.37	TRUE
OSA	Chronic gastritis	322.16	0.38	0.82	0.38	TRUE
OSA	Ulcerative colitis	315.99	0.63	0.27	0.64	TRUE
OSA	Calculus of gallbladder	318.58	0.45	0.56	0.46	TRUE
OSA	Calculus of bile duct	315.68	0.11	0.13	0.12	TRUE
GERD	OSA	213.01	9.95E-06	0.48	<0.00033	TRUE

MR, Mendelian randomization; OSA, Obstructive sleep apnea; GERD, Gastroesophageal reflux disease; Fstat, F-score used to evaluate statistical power; MR-PRESSO, Mendelian Randomization pleiotropy Residual Sum and Outlier.

Global population-based studies observed an 8-33% incidence rate of GERD (11). However, individuals with OSA have much greater rates, ranging from 40% to 60% (45, 46). A retrospective study of 586,377 adults in the USA discovered an independent link between OSA and GERD while considering multiple potential confounders (13). However, another multicenter, cross-sectional, observational study conducted in Turkey (n=1104) found that the severity of OSA did not independently predict the occurrence of GERD (17). Recently, an MR study discovered an implied bidirectional relationship between OSA and GERD (47); however, it was unclear whether the results were affected by shared risk factors, particularly obesity. Our findings, which were based on MR techniques that accounted for obesity, smoking, alcohol use, and T2D, indicated a bidirectional, independent causal link between GERD and OSA. This finding can benefit future research on the comorbidity of the two diseases and the optimization of a joint treatment plan.

The supine position itself increases the occurrence of nocturnal GER (48). GER events can be caused by declining intrathoracic negative pressure and elevating abdominal pressure during apneic episodes in OSA patients. This pressure fluctuation also relaxes and opens the lower esophageal sphincter, worsening GERD symptoms (10, 49). Common symptoms of GERD include heartburn or regurgitation, non-cardiac chest pain, chronic cough, and sore throat (50). Nocturnal uncomfortable symptoms can lead to heightened sleep arousal and diminished sleep duration by influencing the interaction of various neural pathways (51). The gastric content of reflux can irritate edema and cause spasms in the upper airway and larynx, thereby contributing to the collapse of the upper airway (10). Additionally, reflux can stimulate the vagus nerve, cause bronchial constriction (52), and affect normal systolic function of the respiratory muscles (53), potentially leading to sleep apnea. The complex pathophysiology underlying their causal relationship warrants further investigation.

The present investigation found previously unrecognized causal links between a genetic predisposition to OSA and a greater incidence of gastroduodenal ulcer and chronic gastritis. An earlier study conducted by Wu et al. found that OSA could affect duodenal morphology via increased oxidative stress and activation of transcription factors, which can lead to the disruption of intestinal tight junctions, culminating in intestinal damage (54). This disruption may lead to the development of gastroduodenal ulcer. Furthermore, multiple cross-sectional studies have shown that shorter sleep durations and poor sleep quality increase the likelihood of gastroduodenal ulcer recurrence (55, 56). The MVMR analysis showed that OSA's effect on chronic gastritis was diminished after accounting for obesity, possibly indicating that OSA and obesity synergistically contribute to chronic gastritis.

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, represent chronic inflammatory condition of the gastrointestinal tract. The pathogenesis of intestinal lesions in IBD remains elusive. The bidirectional interactions between sleep disorders and IBD have recently received considerable attention (57, 58). OSA causes intermittent hypoxia, which results in periodic reductions in the oxygen partial pressure gradient within the lumen, promoting intestinal dysbiosis and inflammation (59). Disruption of the circadian rhythm can impair normal intestinal immune system activity, leading to an increased release of inflammatory factors and exacerbating intestinal inflammation (60-62). A retrospective study using US-wide diagnostic coding data independently linked IBD to a higher prevalence of OSA (63), consistent with the findings of this MR analysis. The potential causal relationship between genetically predicted OSA and ulcerative colitis identified in this study may provide new perspectives to explore the pathogenesis and treatment of IBD.

Moreover, we observed a positive link between OSA and gallstones, including calculi in the gallbladder and bile duct. This outcome is consistent with the finding from a cross-sectional study conducted by Chen et al. on 3,827 patients (7). OSA may cause gallstones by impeding gallbladder contraction through stimulating sympathetic nerves and enhancing bile supersaturation through inflammation associated with chronic intermittent hypoxia (64, 65). A previous Mendelian analysis showed that 1–standard deviation increase in the body mass index resulted 1.631 times increased odds of developing gallstones (66). However, the current MVMR analysis found that the causal relationship between OSA and gallbladder calculi was no longer significant after considering obesity; the causal relationship with bile duct calculi remained. This result suggests

that OSA may affect gallbladder calculi, but not an independent risk factor.

Recent research has revealed a connection between OSA and the initiation and progression of NAFLD (67), indicating that patients with OSA face poor prognoses and are susceptible to other liver conditions (68, 69). However, MR results did not reveal a significant causal association between genetic predisposition to OSA and the development of NAFLD or cirrhosis. In addition, separate epidemiological studies by Nieto et al. (70) and Marshall et al. (71) reported significantly higher cancer mortality rates among patients with sleep apnea. However, Kendzerska et al. (72) concluded that OSA severity does not increase cancer incidence. Our study found no correlations between genetically predicted OSA and gastrointestinal cancers, including esophageal, gastric, or colorectal cancers. These findings suggest that the observed epidemiological relationships may stem from shared genetic components or unmeasured confounding factors.

This study had several advantages. First, this study is the first to comprehensively assess the cause-and-effect relationship underlying OSA with major GDs. We utilized two-sample MR based on SNPs from large sample populations (33,423 cases and 307,648 controls for OSA; an average of 9,530 cases and 299,113 controls for each GD); the sample sizes for exposure and outcomes did not overlap. Second, multiple MR statistical methods and multivariate MR analyses were applied to minimize confounding bias and guarantee the reliability of the findings, including adjustments for obesity, T2D, smoking, and alcohol consumption.

This study had limitations. First, the summary-level data from the GWASs included trans-ancestry populations among the source populations, as shown in Table 1. This inclusion could bias results because of the possibility of population mixture confounding. Second, MVMR analysis was performed for common risk factors for OSA and GDs, but other potential confounders may have a potential impact on the independence of causal association. Third, completely excluding the possibility that the SNPs linked to GERD affect OSA via additional causative pathways (i.e., horizontal pleiotropy) was challenging.

5 Conclusion

This MR analysis provides compelling evidence of an independent causal relationship between genetically predicted OSA and an elevated risk of multiple inflammation-related GDs. In summary, this study provides strong evidence that OSA and GERD are independent risk factors for each other. In addition, a novel independent causal association was found between genetically predicted OSA and gastroduodenal ulcer. The increased risk of chronic gastritis, ulcerative colitis, and gallstones (including calculus in the gallbladder and bile duct) may also be correlated directly with OSA. Understanding the biological pathways and mechanisms underlying these correlations will aid physicians and researchers in developing preventive and therapeutic strategies for patients with OSA presenting with gastrointestinal symptoms.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

WY: Conceptualization, Data curation, Formal analysis, Methodology, Software, Visualization, Writing – original draft. JZ: Data curation, Investigation, Validation, Writing – original draft. MJ: Conceptualization, Supervision, Validation, Writing – review & editing. YK: Data curation, Formal analysis, Writing – original draft. HQ: Data curation, Visualization, Writing – original draft. YQ: Data curation, Formal analysis, Writing – original draft. SW: Conceptualization, Investigation, Supervision, Validation, Writing – review & editing. JT: Conceptualization, Funding acquisition, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from Public service development and reform pilot project of Beijing Medical Research Institute (BMR2021-3) National natural science foundation of China (82271193), Capital's Funds for Health Improvement and Research (2022-2-1132), Beijing Hospitals Authority's Ascent Plan (DFL20221102), Beijing Hospitals Authority clinical medicine development project (YGLX202335).

Acknowledgments

The authors wish to acknowledge all the participants and investigators for contributing to and sharing summary-level data on the GWAS.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1256116/ full#supplementary-material

SUPPLEMENTARY FIGURE 1

Scatter plot of the effect of the potential causal relationship between OSA and GDs. Figures (A-G) show the MR results in the significant causal relationship between OSA and GDs. The slope equals the b-value calculated using the five methods, representing the causal effect. The positive slope indicates that exposure is a risk factor, whereas a negative slope is the opposite. OSA, Obstructive sleep apnea; GDs, gastrointestinal diseases; MR, Mendelian randomization; SNP, single nucleotide polymorphisms; IVs, instrumental variables.

SUPPLEMENTARY FIGURE 2

Funnel plot of the effect of the potential causal relationship between OSA and GDs. Figures (A–G) show the distribution of IVs in the significant causal relationship between OSA and GDs, respectively. Red boxes indicate potential outliers that were eliminated from the analysis. OSA, Obstructive sleep apnea; GDs, gastrointestinal diseases; MR, Mendelian randomization; SNP, single nucleotide polymorphisms; IVs, instrumental variables; SE, standard error.

References

1. Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, et al. Prevalence of obstructive sleep apnea in the general population: A systematic review. *Sleep Med Rev.* (2017) 34:70–81. doi: 10.1016/j.smrv.2016.07.002

2. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med.* (2019) 7:687–98. doi: 10.1016/S2213-2600(19)30198-5

3. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: A review. JAMA. (2020) 323:1389-400. doi: 10.1001/jama.2020.3514

4. Brodie KD, Goldberg AN. Obstructive sleep apnea: A surgeon's perspective. Med Clin North Am. (2021) 105:885–900. doi: 10.1016/j.mcna.2021.05.010

5. Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, et al. Obstructive sleep apnea and cardiovascular disease: A scientific statement from the american heart association. *Circulation*. (2021) 144:e56-67. doi: 10.1161/CIR.00000000000988

6. Orr WC, Fass R, Sundaram SS, Scheimann AO. The effect of sleep on gastrointestinal functioning in common digestive diseases. *Lancet Gastroenterol Hepatol.* (2020) 5:616–24. doi: 10.1016/S2468-1253(19)30412-1

7. Chen CH, Lin CL, Hsu CY, Kao CH. Risk of gallstones in patients with obstructive sleep apnea: a nationwide observational cohort study. *Sleep Breath*. (2019) 23:355–62. doi: 10.1007/s11325-018-1696-5

8. Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. *Am J Respir Crit Care Med.* (2019) 199:830-41. doi: 10.1164/rccm.201806-1109TR

 Valentin S, Renel B, Manneville F, Caron B, Choukour M, Guillaumot A, et al. Prevalence of and factors associated with respiratory symptoms among patients with inflammatory bowel disease: A prospective study. *Inflamm Bowel Dis.* (2023) 29:207– 16. doi: 10.1093/ibd/izac062

10. Lim KG, Morgenthaler TI, Katzka DA. Sleep and nocturnal gastroesophageal reflux: an update. *Chest.* (2018) 154:963–71. doi: 10.1016/j.chest.2018.05.030

11. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut.* (2014) 63:871–80. doi: 10.1136/gutjnl-2012-304269

12. Pardak P, Filip R, Wolinski J, Krzaczek M. Associations of obstructive sleep apnea, obestatin, leptin, and ghrelin with gastroesophageal reflux. *J Clin Med.* (2021) 10:5195. doi: 10.3390/jcm10215195

13. Gilani S, Quan SF, Pynnonen MA, Shin JJ. Obstructive sleep apnea and gastroesophageal reflux: A multivariate population-level analysis. *Otolaryngol Head Neck Surg.* (2016) 154:390-5. doi: 10.1177/0194599815621557

14. Wang L, Han H, Wang G, Liu H, Sun Z, Li B, et al. Relationship between reflux diseases and obstructive sleep apnea together with continuous positive airway pressure treatment efficiency analysis. *Sleep Med.* (2020) 75:151–5. doi: 10.1016/j.sleep.2020.07.024

15. Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. *Metabolism*. (2016) 65:1124-35. doi: 10.1016/j.metabol.2016.05.004

SUPPLEMENTARY FIGURE 3

MR leave-one-out sensitivity analysis for 'Gastroesophageal reflux disease' on 'OSA'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

SUPPLEMENTARY FIGURE 4

MR leave-one-out sensitivity analysis for 'OSA' on 'Gastroduodenal ulcer'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

SUPPLEMENTARY FIGURE 5

MR leave-one-out sensitivity analysis for 'OSA' on 'Chronic gastritis'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

SUPPLEMENTARY FIGURE 6

MR leave-one-out sensitivity analysis for 'OSA' on 'Ulcerative colitis'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

SUPPLEMENTARY FIGURE 7

MR leave-one-out sensitivity analysis for 'OSA' on 'Calculus of gallbladder'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

SUPPLEMENTARY FIGURE 8

MR leave-one-out sensitivity analysis for 'OSA' on 'Calculus of bile duct'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

SUPPLEMENTARY FIGURE 9

MR leave-one-out sensitivity analysis for 'Gastroesophageal reflux disease' on 'OSA'. MR, Mendelian randomization; OSA, Obstructive sleep apnea.

16. Shepherd K, Orr W. Mechanism of gastroesophageal reflux in obstructive sleep apnea: airway obstruction or obesity? *J Clin Sleep Med.* (2016) 12:87–94. doi: 10.5664/jcsm.5402

17. Basoglu OK, Vardar R, Tasbakan MS, Ucar ZZ, Ayik S, Kose T, et al. Obstructive sleep apnea syndrome and gastroesophageal reflux disease: the importance of obesity and gender. *Sleep Breath*. (2015) 19:585–92. doi: 10.1007/s11325-014-1051-4

18. El Hage Chehade N, Fu Y, Ghoneim S, Shah S, Song G, Fass R. Association between obstructive sleep apnea and gastroesophageal reflux disease: A systematic review and meta-analysis. *J Gastroenterol Hepatol.* (2023) 38:1244–51. doi: 10.1111/ jgh.16245

19. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med.* (2008) 27:1133–63. doi: 10.1002/sim.3034

20. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *Int J Epidemiol.* (2016) 45:1600–16. doi: 10.1093/ije/dyw088

21. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res.* (2017) 26:2333–55. doi: 10.1177/0962280215597579

22. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? *Int J Epidemiol.* (2015) 44:379–88. doi: 10.1093/ije/dyv108

23. Chen W, Cai X, Yan H, Pan Y. Causal effect of obstructive sleep apnea on atrial fibrillation: A mendelian randomization study. *J Am Heart Assoc.* (2021) 10:e022560. doi: 10.1161/JAHA.121.022560

24. Yi M, Zhao W, Fei Q, Tan Y, Liu K, Chen Z, et al. Causal analysis between altered levels of interleukins and obstructive sleep apnea. *Front Immunol.* (2022) 13:888644. doi: 10.3389/fimmu.2022.888644

25. Li J, Zhao L, Ding X, Cui X, Qi L, Chen Y. Obstructive sleep apnea and the risk of Alzheimer's disease and Parkinson disease: A Mendelian randomization study OSA, Alzheimer's disease and Parkinson disease. *Sleep Med.* (2022) 97:55–63. doi: 10.1016/j.sleep.2022.06.004

26. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res.* (2019) 4:186. doi: 10.12688/wellcomeopenres

27. Benn M, Nordestgaard BG. From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. *Cardiovasc Res.* (2018) 114:1192–208. doi: 10.1093/cvr/cvy045

28. Strausz S, Ruotsalainen S, Ollila HM, Karjalainen J, Kiiskinen T, Reeve M, et al. Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health. *Eur Respir J.* (2021) 57:2003091. doi: 10.1183/13993003.03091-2020

29. Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a

histologically characterised cohort(\$\$). J Hepatol. (2020) 73:505-15. doi: 10.1016/j.jhep.2020.04.003

30. Li P, Wang H, Guo L, Gou X, Chen G, Lin D, et al. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. *BMC Med.* (2022) 20:443. doi: 10.1186/s12916-022-02657-x

31. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. *Stat Methods Med Res.* (2012) 21:223–42. doi: 10.1177/0962280210394459

32. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol.* (2017) 32:377–89. doi: 10.1007/s10654-017-0255-x

33. Burgess S, Bowden J, Fall T, Ingelsson EThompson SG. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. *Epidemiology*. (2017) 28:30–42. doi: 10.1097/EDE.00000000000559

34. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol.* (2016) 40:304–14. doi: 10.1002/gepi.21965

35. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* (2015) 44:512–25. doi: 10.1093/ije/dyv080

36. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* (2017) 46:1985–98. doi: 10.1093/ije/dyx102

37. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* (2018) 50:693–8. doi: 10.1038/s41588-018-0099-7

38. Luo Q, Li N, Zhu Q, Yao X, Wang M, Heizhati M, et al. Non-dipping blood pressure pattern is associated with higher risk of new-onset diabetes in hypertensive patients with obstructive sleep apnea: UROSAH data. *Front Endocrinol (Lausanne).* (2023) 14:1083179. doi: 10.3389/fendo.2023.1083179

39. Cai X, Song S, Hu J, Zhu Q, Yang W, Hong J, et al. Body roundness index improves the predictive value of cardiovascular disease risk in hypertensive patients with obstructive sleep apnea: a cohort study. *Clin Exp Hypertens.* (2023) 45:2259132. doi: 10.1080/10641963.2023.2259132

40. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol*. (2015) 181:251–60. doi: 10.1093/aje/kwu283

41. Grant AJ, Burgess S. Pleiotropy robust methods for multivariable Mendelian randomization. *Stat Med.* (2021) 40:5813–30. doi: 10.1002/sim.9156

42. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PloS Genet.* (2017) 13: e1007081. doi: 10.1371/journal.pgen.1007081

43. Hu J, Song J, Chen Z, Yang J, Shi Q, Jin F, et al. Reverse causal relationship between periodontitis and shortened telomere length: Bidirectional two-sample Mendelian random analysis. *Front Immunol.* (2022) 13:1057602. doi: 10.3389/fimmu.2022.1057602

44. Vernia F, Di Ruscio M, Ciccone A, Viscido A, Frieri G, Stefanelli G, et al. Sleep disorders related to nutrition and digestive diseases: a neglected clinical condition. *Int J Med Sci.* (2021) 18:593–603. doi: 10.7150/ijms.45512

45. Chen MJ, Wu MS, Lin JT, Chang KY, Chiu HM, Liao WC, et al. Gastroesophageal reflux disease and sleep quality in a Chinese population. J Formos Med Assoc. (2009) 108:53–60. doi: 10.1016/S0929-6646(09)60032-2

46. Sabate JM, Jouet P, Merrouche M, Pouzoulet J, Maillard D, Harnois F, et al. Gastroesophageal reflux in patients with morbid obesity: a role of obstructive sleep apnea syndrome? *Obes Surg.* (2008) 18:1479–84. doi: 10.1007/s11695-008-9508-9

47. Zhu Q, Hua L, Chen L, Mu T, Dong D, Xu J, et al. Causal association between obstructive sleep apnea and gastroesophageal reflux disease: A bidirectional twosample Mendelian randomization study. *Front Genet.* (2023) 14:1111144. doi: 10.3389/fgene.2023.1111144

48. Schuitenmaker JM, van Dijk M, Oude Nijhuis RAB, Smout A, Bredenoord AJ. Associations between sleep position and nocturnal gastroesophageal reflux: A study using concurrent monitoring of sleep position and esophageal pH and impedance. *Am J Gastroenterol.* (2022) 117:346–51. doi: 10.14309/ajg.000000000001588

49. Kuribayashi S, Kusano M, Kawamura O, Shimoyama Y, Maeda M, Hisada T, et al. Mechanism of gastroesophageal reflux in patients with obstructive sleep apnea syndrome. *Neurogastroenterol Motil.* (2010) 22:611–e172. doi: 10.1111/nmo.2010.22.issue-6

50. Yadlapati R, Gyawali CP, Pandolfino JE. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. *Clin Gastroenterol Hepatol.* (2022) 20:984–994.e1. doi: 10.1016/j.cgh.2022.01.025

51. Qin S, Wang C, Wang X, Wu W, Liu C. Causal association of gastroesophageal reflux disease with obstructive sleep apnea and sleep-related phenotypes: a bidirectional two-sample Mendelian randomization study. *Front Neurol.* (2023) 14:1283286. doi: 10.3389/fneur.2023.1283286

52. Cazzola M, Calzetta L, Matera MG. Long-acting muscarinic antagonists and small airways in asthma: Which link? *Allergy.* (2021) 76:1990–2001. doi: 10.1111/ all.14766

53. Giordano F, Zicca A, Barba C, Guerrini R, Genitori L. Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity. *Epilepsia*. (2017) 58 Suppl 1:85–90. doi: 10.1111/epi.13678

54. Wu J, Sun X, Wu Q, Li H, Li L, Feng J, et al. Disrupted intestinal structure in a rat model of intermittent hypoxia. *Mol Med Rep.* (2016) 13:4407–13. doi: 10.3892/mmr.2016.5068

55. Fang B, Liu H, Yang S, Xu R, Chen G. Sleep duration, depression, and peptic ulcer recurrence in older patients with mild cognitive impairment. *Health Psychol.* (2020) 39:77–87. doi: 10.1037/hea0000814

56. Fang B, Liu H, Yang S, Xu R, Chen G. Effect of subjective and objective sleep quality on subsequent peptic ulcer recurrence in older adults. *J Am Geriatr Soc.* (2019) 67:1454–60. doi: 10.1111/jgs.15871

57. Qazi T, Farraye FA. Sleep and inflammatory bowel disease: an important bidirectional relationship. *Inflamm Bowel Dis.* (2019) 25:843–52. doi: 10.1093/ibd/izy334

58. Ballesio A, Zagaria A, Baccini F, Micheli F, Di Nardo G, Lombardo C. A metaanalysis on sleep quality in inflammatory bowel disease. *Sleep Med Rev.* (2021) 60:101518. doi: 10.1016/j.smrv.2021.101518

59. Hatamnejad MR, Baradaran Ghavami S, Shirvani M, Asghari Ahmadabad M, Shahrokh S, Farmani M, et al. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. *Front Immunol.* (2022) 13:980189. doi: 10.3389/fimmu.2022.980189

60. Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol. (2013) 13:190-8. doi: 10.1038/nri3386

61. Parekh PJ, Oldfield Iv EC, Challapallisri V, Ware JC, Johnson DA. Sleep disorders and inflammatory disease activity: chicken or the egg? *Am J Gastroenterol.* (2015) 110:484–8. doi: 10.1038/ajg.2014.247

62. Gombert M, Carrasco-Luna J, Pin-Arboledas G, Codoñer-Franch P. The connection of circadian rhythm to inflammatory bowel disease. *Transl Res.* (2019) 206:107–18. doi: 10.1016/j.trsl.2018.12.001

63. Hoffman K, Mansoor E, Panhwar MS, Regueiro M, Cooper G, Qazi T. Prevalence of obstructive sleep apnea is increased in patients with inflammatory bowel disease: A large, multi-network study. *Crohns Colitis* 360. (2022) 4:otac026. doi: 10.1093/crocol/otac026

64. Lammert F, Gurusamy K, Ko CW, Miquel JF, Mendez-Sanchez N, Portincasa P, et al. Gallstones. *Nat Rev Dis Primers*. (2016) 2:16024. doi: 10.1038/nrdp.2016.24

65. Unnikrishnan D, Jun J, Polotsky V. Inflammation in sleep apnea: an update. *Rev Endocr Metab Disord*. (2015) 16:25–34. doi: 10.1007/s11154-014-9304-x

66. Chen L, Yang H, Li H, He C, Yang L, Lv G. Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study. *Hepatology*. (2022) 75:785–96. doi: 10.1002/hep.32183

67. Umbro I, Fabiani V, Fabiani M, Angelico F, Del Ben M. Association between non-alcoholic fatty liver disease and obstructive sleep apnea. *World J Gastroenterol.* (2020) 26:2669–81. doi: 10.3748/wjg.v26.i20.2669

68. Chou TC, Liang WM, Wang CB, Wu TN, Hang LW. Obstructive sleep apnea is associated with liver disease: a population-based cohort study. *Sleep Med.* (2015) 16:955–60. doi: 10.1016/j.sleep.2015.02.542

69. Trzepizur W, Boursier J, Le Vaillant M, Ducluzeau PH, Dubois S, Henni S, et al. Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities. *Eur Respir J.* (2018) 51:1800601. doi: 10.1183/13993003.00601-2018

70. Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farre R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. *Am J Respir Crit Care Med.* (2012) 186:190–4. doi: 10.1164/rccm.201201-0130OC

71. Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. *J Clin Sleep Med.* (2014) 10:355–62. doi: 10.5664/jcsm.3600

72. Kendzerska T, Leung RS, Hawker G, Tomlinson G, Gershon AS. Obstructive sleep apnea and the prevalence and incidence of cancer. *CMAJ.* (2014) 186:985–92. doi: 10.1503/cmaj.140238